

Short Name	Full Title + Study Description	Type	Investigator	Contact
Stop-AF	STOP AF: Provide data demonstrating the safety and effectiveness of the Arctic Front Advance™ Cardiac Cryoablation Catheter	Device	Dr. Andre Gauri	Jared Bush Jared.Bush@spectrumhealth.org 616.486.2298
	<i>The purpose of the study is to provide data demonstrating the safety and effectiveness of the Artic Front Advance™ Cardiac CryoAblation Catheter for the treatment of recurrent symptomatic paroxysmal AF, without the requirement that the subjects be drug refractory.</i>			
TERMINATE - AF	Irrigated Radio Frequency Ablation to Terminate Non-paroxysmal Atrial Fibrillation.	Device	Dr. Edward Murphy	Mary Ragagni Mary.Ragagni@spectrumhealth.org 616.267.1813
	<i>The purpose of this study is to evaluate the safety and effectiveness of the Cardioblade and Cryoflex hand held devices to treat persistent atrial fibrillation in subjects undergoing concomitant cardiac surgery.</i>			
Prevent-AF	Prophylactic Limited Left-Sided Maze to Prevent Postoperative Atrial Fibrillation in Adult Cardiac Surgery Patients	Device	Dr. Charles Willekes	Mary Ragagni Mary.Ragagni@spectrumhealth.org 616.267.1813
	<i>This is a research study for patients having first time open heart surgery who are randomized to also have a surgical maze procedure at the same time in hopes of preventing post-operative atrial fibrillation, which is a common occurrence after heart surgery.</i>			
CATALYST Trial	Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants	Device	Dr. Duane Berkompas	Rachel Cameron Rachel.Cameron@spectrumhealth.org 616.391.9360

This clinical investigation is intended to evaluate the safety and effectiveness of Abbott's Amplatzer™ Amulet™ Left Atrial Appendage (LAA) occluder device compared to commercially available non-vitamin K antagonist oral anticoagulant (NOAC) drugs in patients with non-valvular atrial fibrillation (AF) who are at increased risk for ischemic stroke and who are tolerant of long-term NOAC therapy.

Elizabeth Helm
Elizabeth.Helm@spectrumhealth.org
616.486.2080
